



20th Annual Meeting of the GU Medical Oncologists of Canada (GUMOC)



Genitourinary Medical Oncologists of Canada
Oncologues Génito-urinaires Médicaux du Canada

Friday June 27, 2025 – 08:00-16:30 ET



Westin Hotel, Ottawa | GOVERNOR GENERAL 1-2 | LEVEL 4



JUNE
27
FRI

AGENDA

07:30 - 09:00 GUMOC Registration & Hot breakfast

CUA Educational Session #2

08:00 - 08:50

Advanced Bladder Cancer

GOVERNOR GENERAL 1-2 | LEVEL 4

*Pre-registration recommended - seats are limited.

09:00 - 09:05

Welcome & Opening remarks

Meeting Chairs: Michael Ong, Ana Beltran-Bless and Dominick Bossé

09:05 - 09:10

Meeting Introduction

Srikala Sridhar + Meeting Chairs

Technical startup – POLL-EV login

SESSION 1 | Hot GU Topics & Crowdsourcing Solutions

Moderators: Jeffrey Graham, Lori Wood

09:10 - 09:20

Which patient should we be choosing for radioligand therapy, given that it is a highly limited resource in Canada?

Lillian Hanna

09:20 - 09:30

Discussion/Q&A

09:30 - 09:40

Muscle-invasive bladder cancer post Cis-Gem-Durvalumab or (in the future) EV-Pembrolizumab: What do we do with patients with complete clinical response who refuse surgery?

David Maj

09:40 - 09:50

Discussion/Q&A

09:50 - 10:00

How can we leverage and work together in Canada on results of large gene sequencing panels in common and rare GU malignancies?

Guliz Ozgun

10:00 - 10:10

Discussion/Q&A

10:10 - 10:30

Practice Sharing across Canada

Christina Canil, Neil Reaume

10:30 - 10:45

Networking Health Break

JUNE
27
FRI

AGENDA

SESSION 2 | Radioligand Therapy in Prostate Cancer

Moderators: Ali Fawaz, April Rose

- 10:45 - 11:05 **KEYNOTE SPEAKER: How do we deliver value now and in the future for prostate cancer patients with RLT?**
Tanya Dorff
- 11:05 - 11:15 **Discussion/Q&A**
- 11:15 - 11:50 **Introduction and Pre-Debate Vote**
PRO: In ARPI-exposed mCRPC patients, ARPI should ALWAYS be continued at the same time as Ra223 and PSMA-Lu177
Cristiano Ferrario
CON: In ARPI-exposed mCRPC patients, ARPI should NEVER be continued at the same time as Ra223 and PSMA-Lu177
Scott North
Questions, Concluding remarks and Post-Debate Vote
- 11:50 - 12:05 **How should we develop more personalized approaches to mCSPC treatment (de)intensification?**
Daniel Khalaf
- 12:05 - 13:00 **Group photo and networking lunch**

SESSION 3 | Immunotherapy and Therapeutic Targets in Prostate Cancer

Moderators: Urban Emmeneger, Zineb Hamilou

- 13:00 - 13:20 **Is there a future where more patients with prostate cancer patients receive immunotherapy?**
Tanya Dorff
- 13:20 - 13:30 **Discussion/Q&A**
- 13:30 - 13:45 **PARP inhibitors for prostate cancer: Few, many or all?**
Kim Chi
- 13:45 - 13:55 **Discussion/Q&A**
- 13:55 - 14:05 **Can we successfully roll out T-Cell engagers programs for GU research in Canada?**
Michael Ong
- 14:05 - 14:15 **Discussion/Q&A**
- 14:15 - 14:25 **Networking Health Break**

JUNE
27
FRI

AGENDA

SESSION 4 | The Evolving Landscape of Bladder and Kidney Cancer

Moderators: Ana-Beltran Bless, Aly-Khan Lalani

- 14:25 - 14:55** Introduction and Pre-Debate Vote
PRO: Platinum chemotherapy is an important option post-EV Pembro
Nimira Alimohamed (10 min)
CON: Platinum chemotherapy is NOT an important option post-EV Pembro
Karine Tawagi (10 min)
Concluding remarks and Post-Debate Vote
- 14:55 - 15:05** When and how to successfully deliver FGFR inhibitors in metastatic urothelial carcinoma.
Bernie Eigl
- 15:05 - 15:15** Discussion/Q&A
- 15:15 - 15:25** Practical Considerations for Toxicity Management of Belzutifan, Erdafitinib, and Enfortumab
Maria Jiang, Ramy Saleh
- 15:25 - 15:35** Discussion/Q&A
- 15:35 - 16:00** CANADIAN TRIVIA GAME SHOW
Host: Rodney Breau
East vs West Canada
- 16:00 - 16:30** GUMOC Business Meeting
- 16:30 - 17:30** **CUA Educational Session #3**
Prostate Cancer
GOVERNOR GENERAL 1-2 | LEVEL 4
*Pre-registration recommended - seats are limited.
- 19:00** Private networking event for GUMOC members and faculty only.

GOLD SPONSORS



SILVER SPONSORS



This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the CUA. You may claim a maximum of 6.5 hours of credit.